<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Pharmaceutical on FinanClub</title>
    <link>https://finan.club/tags/pharmaceutical/</link>
    <description>Recent content in Pharmaceutical on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Mon, 11 Sep 2023 05:39:30 +0000</lastBuildDate><atom:link href="https://finan.club/tags/pharmaceutical/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>VTRS</title>
      <link>https://finan.club/us/vtrs/</link>
      <pubDate>Mon, 11 Sep 2023 05:39:30 +0000</pubDate>
      
      <guid>https://finan.club/us/vtrs/</guid>
      <description>score:-49
Chances: Viatris Inc. (VTRS) has been gaining attention as a pharmaceutical stock that may be undervalued. The company recently received tentative approval from the FDA for a pediatric HIV regimen, which could open new revenue streams. Viatris reported strong Q2 2023 earnings with growth in its generics business, indicating positive performance.</description>
    </item>
    
    <item>
      <title>GSK</title>
      <link>https://finan.club/us/gsk/</link>
      <pubDate>Mon, 11 Sep 2023 04:54:38 +0000</pubDate>
      
      <guid>https://finan.club/us/gsk/</guid>
      <description>score:-20
Chances: GSK&amp;rsquo;s value is being questioned, but it may be undervalued, making it an attractive investment option. GSK announces availability of AREXVY, its Respiratory Syncytial Virus (RSV) vaccine, at all major US retail pharmacies. Settling the first Zantac cancer lawsuit could soothe investors and impact GSK&amp;rsquo;s stock positively.</description>
    </item>
    
  </channel>
</rss>
